International Study to Evaluate Efficacy and Safety in Treating a Leading Cause of Blindness LEVERKUSEN, Germany, MONTVILLE, New Jersey and TARRYTOWN, New York, May 8 /PRNewswire-FirstCall/...
Merger to be Completed Shortly LEVERKUSEN, Germany and PITTSBURGH, Pennsylvania, April 2 /PRNewswire-FirstCall/ -- Bayer HealthCare affiliate MEDRAD, Inc. announced today the completion of its...
Subsequent Offering Period Expires on Tuesday, April 1, 2008 LEVERKUSEN, Germany, and PITTSBURGH, Pennysylvania, March 26 /PRNewswire-FirstCall/ -- Bayer HealthCare affiliate MEDRAD, Inc...
Study Data Demonstrated Improved Progression-free Survival with Campath CAMBRIDGE, Mass. and WAYNE, N.J., Sept. 20 /PRNewswire-FirstCall/ -- Genzyme Corp. (NASDAQ:GENZ) and Bayer HealthCare...
Survey reveals majority of homeowners believe they have less free time than five years ago RESEARCH TRIANGLE PARK, N.C., Aug. 27 /PRNewswire-FirstCall/ -- Bayer Lawn Care Institute today...
LEVERKUSEN, Germany, June 19 /PRNewswire-FirstCall/ -- Today Bayer CropScience has completed the acquisition of Stoneville Pedigreed Seed Company from Monsanto Company after US authorities...
Honors Alaskan Winner of UNEP's 16th International Children's Painting Competition PITTSBURGH, June 5 /PRNewswire-USNewswire/ -- Furthering its commitment to both science education and...
Acquisition of leading US cotton business expected to bolster growth strategy LEVERKUSEN, Germany, May 31 /PRNewswire/ -- Bayer CropScience announced today that it has entered into an agreement...
NEW YORK, Jan. 9 /PRNewswire-USNewswire/ -- A recent telephone survey found that among people who take medication for a cold or the flu, 40 percent take multiple medications to treat their...
Spreading Out Home Maintenance Expenses Throughout the Year Will Keep Budgets on Track and Your Home Looking Great RALEIGH, N.C., Sept. 7 /PRNewswire/ -- Owning a home can quickly turn from...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales